Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93195856 | 9319585 | 6 | F | 20160701 | 20160921 | 20130530 | 20160927 | EXP | US-GLAXOSMITHKLINE-A1009753A | GLAXOSMITHKLINE | 73.17 | YR | F | Y | 0.00000 | 20160927 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93195856 | 9319585 | 1 | PS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | CONTINUOUS56 NG/KG/MIN, 60000 NG/ML | U | N145 | 20444 | 56 | DF | POWDER FOR INFUSION | |||||
| 93195856 | 9319585 | 2 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | UNK | U | R852 | 20444 | POWDER FOR INFUSION | ||||||||
| 93195856 | 9319585 | 3 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | CONTINUOUS 61 NG/KG/MIN | U | V049 | 20444 | 61 | DF | POWDER FOR INFUSION | ||||||
| 93195856 | 9319585 | 4 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | 62 DF, CO | U | Z606 | 20444 | 62 | DF | POWDER FOR INFUSION | ||||||
| 93195856 | 9319585 | 5 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 63 NG/KG/MIN, CO | U | Z880 | 20444 | 63 | DF | POWDER FOR INFUSION | |||||
| 93195856 | 9319585 | 6 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | U | C762537 | 0 | SOLUTION FOR INJECTION | |||||||||
| 93195856 | 9319585 | 7 | C | REVATIO | SILDENAFIL CITRATE | 1 | U | 0 | |||||||||||
| 93195856 | 9319585 | 8 | C | COUMADIN | WARFARIN SODIUM | 1 | U | 0 | |||||||||||
| 93195856 | 9319585 | 9 | C | TRACLEER | BOSENTAN | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 93195856 | 9319585 | 1 | Pulmonary arterial hypertension |
| 93195856 | 9319585 | 6 | Pulmonary arterial hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 93195856 | 9319585 | HO |
| 93195856 | 9319585 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 93195856 | 9319585 | Abdominal discomfort | |
| 93195856 | 9319585 | Central venous catheterisation | |
| 93195856 | 9319585 | Chest pain | |
| 93195856 | 9319585 | Device related infection | |
| 93195856 | 9319585 | Dyspnoea | |
| 93195856 | 9319585 | Sinusitis | |
| 93195856 | 9319585 | Therapy cessation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 93195856 | 9319585 | 1 | 20030321 | 0 | ||
| 93195856 | 9319585 | 2 | 20030321 | 0 |